Replimune Group, Inc. (REPL) stock
Close on Nov 11, 2026Market cap $2.06BP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $2.06B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 10.08
- Dividend yield
- –
- Free cash flow yield
- -11.90%
Fundamentals
- Net income
- -$271.03M
- EPS, diluted
- -$2.80
- Free cash flow
- -$245.77M
- Book value per share
- $1.95
- Diluted shares
- 105M
Trading
- Next earnings
- Feb 2, 2027 (estimated, before the open)
- Previous close
- $23.28
- Open
- $23.54
- Day's range
- $21.74 – $23.54
- Volume
- 3,031,865
- Average volume (20 days)
- 3,332,833
- Index membership
- Russell 2000, Russell 3000
- Beta (5 years)
- 0.65
- 52-week range
- $1.50 – $23.54
- RSI (14 days)
- 72.2
- Volatility (1 year)
- 187.6%
- Relative volume
- 0.80×
- WACC
- 8.1%
On 2 of our idea lists: Institutions accumulating, Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2018, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | REPL | S&P 500 | Difference | REPL per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +62.3% | -2.4% | +64.7 pts | ||
| 3 months | +59.6% | -1.2% | +60.7 pts | ||
| Year to date | +124.1% | +12.3% | +111.8 pts | ||
| 1 year | +138.6% | +12.4% | +126.1 pts | ||
| 3 years | +96.0% | +78.8% | +17.2 pts | +25.2% | +21.4% |
| 5 years | -35.4% | +75.2% | −110.6 pts | -8.4% | +11.9% |
Eleven years at a glance
Fiscal years 2016 to 2026 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Replimune filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- News
- News
- News
- News
About Replimune
Biological Products, (No Diagnostic Substances)
The company is a clinical-stage biotechnology firm that develops oncolytic immunotherapies designed to activate the immune system against cancer. Its proprietary RPx platform utilizes an engineered herpes simplex virus type 1 to selectively destroy tumor cells and stimulate systemic anti-tumor responses. The pipeline includes lead drug candidate RP1, evaluated for advanced melanoma, non-melanoma skin cancers, and skin cancers in organ transplant recipients, as well as RP2, which targets metastatic uveal melanoma and other solid tumors. These therapies serve adult cancer patients, particularly individuals with advanced or treatment-resistant malignancies.
Company profile, executives and historyReplimune stock: common questions
What is Replimune's stock price?
REPL closed at $21.78 on Nov 11, 2026, down 6.44% on the day. Over the past 52 weeks it traded between $1.50 and $23.54.
What is Replimune's market cap?
Replimune was worth $2.06B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is REPL's P/E ratio?
Replimune lost money over the twelve months to Sep 30, 2026 (diluted EPS -$2.80), so it has no meaningful P/E ratio.
Does Replimune pay a dividend?
No. Replimune has not paid a cash dividend over the last twelve months.
When does Replimune report earnings next?
Replimune is expected to report Q3 FY2027 results on Feb 2, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has REPL stock performed over the past year?
Including dividends, REPL returned +138.6% over the past year, against +12.4% for the S&P 500.
How many REPL shares are sold short?
25M shares were sold short at the latest FINRA report, 30.42% of the float, or 8.3 days of average trading volume.
Who are Replimune's competitors?
Companies most similar to Replimune by business, industry and size include CADL, IMCR, FATE, CLDI, IOVA.
See a number that looks wrong?